Venlafaxine-Associated Hepatitis

Cardona, Xavier; Ávila, Asunción; Castellanos, Pere

doi:10.7326/0003-4819-132-5-200003070-00016

Cited by 35 publications

(10 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9,10 VEN has been associated with cholestatic as well as hepatocellular liver damage in patients without a preceding history of liver dysfunction or marked alcohol use. 11 Detry et al, reported a case of a 48-year-old depressed patient who manifested fulminant hepatic failure with a further liver transplantation after developing toxic liver injury, jaundice and encephalopathy. 12 Various environmental compound, drugs and xenobiotics induce their deleterious side effects thorough increased reactive oxygen species (ROS) production.…”

Section: Introductionmentioning

confidence: 99%

Venlafaxine-Induced Cytotoxicity Towards Isolated Rat Hepatocytes Involves Oxidative Stress and Mitochondrial/Lysosomal Dysfunction

Ahmadian¹,

Babaei²,

Nayebi³

et al. 2016

Adv Pharm Bull

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Venlafaxine-Induced Cytotoxicity Towards Isolated Rat Hepatocytes Involves Oxidative Stress and Mitochondrial/Lysosomal Dysfunction

Ahmadian¹,

Babaei²,

Nayebi³

et al. 2016

Adv Pharm Bull

View full text Add to dashboard Cite

“…86 Consensus advice, therefore, is to aim for a maintenance dose of 50% of that which would be aimed for in healthy patients, with subsequent titration based upon the balance of efficacy and side effects. SSRIs and selective noradrenergic reuptake inhibitors (SNRIs) have been associated with hepatoxicity in isolated reports in non-CLD patients which reversed on discontinuation of the drug, including venlafaxine, 78 citalopram, 87 and fluoxetine, paroxetine and sertraline. 88 In a series of seven cases of duloxetine-induced liver injury, three had pre-existing chronic liver disease and one had acute decompensation with jaundice and ascites.…”

mentioning

confidence: 99%

Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

Mullish

Kabir

Thursz

et al. 2014

Aliment Pharmacol Ther

115

View full text Add to dashboard Cite

SummaryBackgroundThe scale of depression in patients with chronic liver disease (CLD) and those who have received orthotopic liver transplantation (OLT) is poorly characterised. Clinicians are uncertain of how best to manage depression within these patients.AimsTo review the literature evaluating both the prevalence and impact of depression in patients with CLD and post‐OLT, and to assess the safety and efficacy of antidepressant use within this context.MethodsA PubMed search using the phrases ‘chronic liver disease’, ‘cirrhosis’, ‘liver transplantation’, ‘depression’, ‘antidepressant’ and the names of specific causes of liver disease and individual antidepressants.ResultsOver 30% of cirrhotic patients have depressive features, and they experience worse clinical outcomes than nondepressed cirrhotic patients. CLD patients with chronic hepatitis C are particularly prone to depression, partly related to the use of interferon therapy. OLT patients with depression have higher mortality rates than nondepressed patients; appropriate antidepressant use reverses this effect. Selective serotonin reuptake inhibitors (SSRIs) and selective noradrenaline reuptake inhibitors (SNRIs) are effective and generally safe in both CLD and OLT patients.ConclusionsDepression is much more prevalent in CLD or OLT patients than is generally recognised, and it adversely affects clinical outcomes. The reasons for this relationship are complex and multifactorial. Antidepressants are effective in both CLD and post‐OLT, although lower doses or a reduced dosing frequency may be required to minimise side effects, e.g. exacerbation of hepatic encephalopathy. Further research is needed to establish optimal management of depression in these patients, including the potential role of nonpharmacological treatments.

show abstract

“…46±3.14 µ/l and 5.55± 0.46 µ/l respectively, while the other hepatic parameters were not altered significantly. (Cardona et al, 2000-Wallace, 2004.…”

Section: Discussionmentioning

confidence: 99%

Effect on Hepatic Parameters and Hepatocytes following administration of antihypertensive, hypolipidemic and hypoglycemic drugs in combination (Part II)

Siddiq¹

2013

J. App. Pharm. Sci.

View full text Add to dashboard Cite

Liver damage is the serious additive effect of drugs used for the treatment of patients suffers from diabetes, hypertension and hyperlipidemia. In continuation of our previous published research the present study is done to evaluate the toxic effects of combination of drugs prescribed for above stated diseases. Combinations of drugs were given to rabbits for the period of two months and their effects on liver function tests were observed. As compared to control rabbits, the combination Acarbose, Lisinopril and Atorvastatin showed increased Glutamic-Pyruvic Transaminase (GPT), Alkaline Phosphatase (ALP) and Gamma glutamyl transferase (γ-GT) (p <0.005), while the animals received combination Metformin, Amlodipine and Atorvastatin showed significant decrease in Alkaline Phosphatase (ALP) and Gamma glutamyl transferase (γ-GT) (p <0.005). The study proved increased in toxic effect of these drugs on hepatocytes when above combination are given, however, Glibenclamide, Losartan and Atorvastatin seems to be safer then others combinations given.

show abstract

Venlafaxine-Associated Hepatitis

Cited by 35 publications

References 1 publication

Venlafaxine-Induced Cytotoxicity Towards Isolated Rat Hepatocytes Involves Oxidative Stress and Mitochondrial/Lysosomal Dysfunction

Venlafaxine-Induced Cytotoxicity Towards Isolated Rat Hepatocytes Involves Oxidative Stress and Mitochondrial/Lysosomal Dysfunction

Review article: depression and the use of antidepressants in patients with chronic liver disease or liver transplantation

Effect on Hepatic Parameters and Hepatocytes following administration of antihypertensive, hypolipidemic and hypoglycemic drugs in combination (Part II)

Contact Info

Product

Resources

About